Formation of reagent-selective products from 2-(4,5-dihydrothi- azol-2-ylthio)-1-arylethanone with different nucleophiles
摘要:
The reactions of 2-(4,5-dihydrothiazol-2-ylthio)-1-arylethanone with different nucleophiles including semicarbazide hydrochloride, hydroxylamine hydrochloride, hydrazine, ethylenediamine and aminoethanol have been investigated, and the formation of a variety of products with different reagents is highlighted.[GRAPHICS].
DOI:
10.1080/17415993.2010.533772
作为产物:
描述:
thallium (I) salt of thiazolidine-2-thione 、 2-溴苯乙酮 以
四氢呋喃 为溶剂,
以85%的产率得到2-(4,5-dihydro-1,3-thiazol-2-ylsulfanyl)-1-phenyl-1-ethanone
参考文献:
名称:
Studies on the structure of some derivatives of 1,3-thiazolidine-2-thione and Δ2-1,3-thiazoline-2-thiol
Thiazines and thiazoles as agents for protecting materials
申请人:——
公开号:US20030129081A1
公开(公告)日:2003-07-10
The novel and known thiazines and thiazoles of the formula (I)
1
in which
R
1
, R
2
and n are as defined in the description, are highly suitable for use as biocides for protecting industrial materials.
Synthesis of difluorinated β-ketosulfones and novel gem-difluoromethylsulfone-containing heterocycles as fluorinated building blocks
作者:Hossein Loghmani-Khouzani、Dariush Hajiheidari
DOI:10.1016/j.jfluchem.2009.12.022
日期:2010.5
A series of new heterocyclic β-ketosulfides was prepared by the reaction of the corresponding heterocyclic thiols with α-bromoacetophenone and its derivatives. Oxidation of the products using m-CPBA gave the corresponding heterocyclic β-ketosulfones, which, on treatment with Selectfluor™ under anhydrous condition underwent electrophilic fluorination resulting in new heterocycles with difluoromethylene
Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
申请人:Wash L. Paul
公开号:US20050026907A1
公开(公告)日:2005-02-03
Disclosed herein are carbonyl compounds of Formula I, II, or III, and others as described herein.
Also disclosed are methods of treating disease, such as cancer, neurological disorders, including polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, autoimmune diseases and cardiovascular conditions, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.